Sponsor:
Novartis Pharmaceuticals
Code:
NCT07850752
Conditions
IgA Nephropathy (IgAN)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
zigakibart
atrasentan
Placebo
Brief summary:
Conditions
IgA Nephropathy (IgAN)
Study ID
NCT07850752
Start date
Nov 11, 2026
Status verified date
Nov, 2026
Completion date
Dec 25, 2030
Anticipated
Primary completion date
Sep 17, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
340 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: zigakibart + atrasentan
active comparator: zigakibart + placebo
Interventions
zigakibart
atrasentan
Placebo
Primary outcome measure
Central contacts
Novartis Pharmaceuticals
+41613241111Locations
Nephrology Consultants LLC
Recruiting
Huntsville, Alabama, United States, 35805
Contacts
Principal Investigator:
Michael Quadrini
West Coast Kidney Institute
Recruiting
Fremont, California, United States, 94538
Contacts
Principal Investigator:
Varun Chawla
Nephrology Associates PA
Recruiting
Newark, Delaware, United States, 19713
Contacts
Nicole Davis
ndavis@delawarekidney.comPrincipal Investigator:
Theodore Saad
Florida Kidney Physicians
Recruiting
Riverview, Florida, United States, 33578
Contacts
Myra Rodriguez
mrodriguez@panoramichealth.comPrincipal Investigator:
Amit Johnsingh
Florida Kidney Physicians LLC
Recruiting
Temple Terrace, Florida, United States, 33637
Contacts
Bianca Philippe
bphilippe@panoramichealth.comPrincipal Investigator:
Wayne Robert Kotzker
Southeast Kidney Associates
Recruiting
East Point, Georgia, United States, 30344
Contacts
Principal Investigator:
Charmaine Emelife
DaVita Clinical Research
Recruiting
Las Vegas, Nevada, United States, 89146
Contacts
Farzana Siddiqui
farzana.siddiqui@davita.comPrincipal Investigator:
Mark Vishnepolsky
Northern Assoc of Northern VA
Recruiting
Fairfax, Virginia, United States, 22033
Contacts
Principal Investigator:
Ahmadshah Mirkhel
Sponsor
Novartis Pharmaceuticals
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.